Then, the DESTINY-Lung01, an open-label phase 2 trial, used T-DXd at a dose of 6.4 mg/kg in treatment-refractory HER2-OE or HER2-mutant NSCLC. Here, ERBB2 is linked to non-small cell lung carcinoma.